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Generalised Lymphatic Dysplasia is a rare condition that may be associated with signiﬁcant chylo-
thoraces. The management of such effusions is often challenging. We present the case of a 15-year-old
girl with bilateral chylothoraces and lymphoedema of her limbs. A clinical diagnosis of Generalised
Lymphatic Dysplasia was made and long-term treatment with somatostatin analogues (somatostatin
initially followed by monthly octreotide) was initiated. Over 12 months there was symptomatic beneﬁt
with some objective improvement in lung function and no adverse effects. After a year of treatment there
was some reaccumulation of ﬂuid, however this did not require any intervention. This is the ﬁrst
paediatric report of the use of somatostatin analogues to manage chylothorax in Generalised Lymphatic
Dysplasia and we conclude that they represent a potentially useful treatment modality. Experience is
only anecdotal however and further studies are required to establish an evidence base with regard to
efﬁcacy and safety.
 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Generalised Lymphatic Dysplasia is a rare condition affecting
1.15/100,000 people aged <20 years.1 Historically patients have
been divided according to age of onset, however an improved
classiﬁcation based on phenotype has recently been published.2
Clinical presentation is variable and may include systemic
involvement such as pleural effusions.2,3 In this context pleural
effusions are recognised to be difﬁcult to manage and are often
refractory to conventional treatment approaches.42. Case report
A 15-year-old girl was referred to tertiary paediatric respiratory
services following identiﬁcation of bilateral pleural effusions
during investigation of delayed puberty. She had initially presented
with lymphoedema complicated by cellulitis in both lower limbs at
2 years of age and was managed with antibiotics and support
stockings. Limb oedema then subsequently increased throughout
childhood.ecretaries, Old Children’s Out
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-NC-ND license.On examination there was signiﬁcant bilateral lymphoedema of
the legs and arms. Hypertrophied and discoloured coloured nails
(Fig. 1) were discovered after removal of nail varnish. A plain
radiograph and computed tomogram of the chest demonstrated
hyperinﬂation and bilateral pleural effusions, but no evidence of
bronchiectasis or mediastinal abnormality. Echocardiography was
normal apart from a small pericardial effusion. Thoracocentesis
yielded milky ﬂuid (protein 45 g/L, cholesterol 3.2 mmol/L,
triglycerides 13.8 mmol/L, lactate dehydrogenase 120U/L, pH 7.75,
white blood cells 0.79  109/L, 98% lymphocytes). A radionuclide
lymphatic study demonstrated a symmetrical obstructive pattern
proximally with extensive collateralisation in both legs and no
pooling in the chest. Serum immunoglobulins, immunoglobulin G
subsets and functional antibodies relating to vaccinations were all
normal.
A clinical diagnosis of Generalised Lymphatic Dysplasia was
made and therapeutic thoracocentesis was performed. The patient
was then established on subcutaneous somatostatin followed by
monthly long-acting octreotide. Prophylactic co-trimoxazole and
a low-fat diet were also instituted. Review at 3 months showed
improved lung function from presentation (FEV1/FVC: 1.5/1.7 L vs.
1.07/1.16 L) with no reaccumulation of pleural ﬂuid.
A year after initial assessment lung function had fallen slightly
(FEV1/FVC 1.25/1.8 L) and the left-sided effusion had re-
accumulated to a degree. However the patient reported
Fig. 1. Discoloured nails.
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repeat thoracocentesis has not been required. In addition, there
have been no adverse effects from somatostatin therapy and it has
been well tolerated. Menarche has now occurred.
3. Discussion
In the Generalised Lymphatic Dysplasias abnormalities of
lymphatic vessels result in impaired lymph drainage, but relatively
little is known about the exact pathogenesis. Mutations in biolog-
ically plausible genes have been implicated in some cohorts and
families with GLD.5,6 Lymphoedema is often associated with dis-
coloured nails. It is important to note that Yellow Nail Syndrome is
a speciﬁc clinical entity, which is often associated with autoim-
munity, lymphoedema and respiratory tract involvement, and
normally presents in later adulthood. The associated nail changes
include slow growth, yellow or green discolouration, increased
transverse and longitudinal curvature, onycholysis, shedding,
cross-ridging and loss of lunalae and cuticles. Misdiagnosis of
Yellow Nail Syndrome is relatively common and it was not the
diagnosis in this case.6
Somatostatin analogues have been used to treat chylous pleural
effusions of varying aetiology including congenital chylothoraces
and trauma to the thoracic duct after cardiothoracic surgery.7,8
There are only limited reports in the adult literature of the use of
somatostatin analogues to treat refractory pleural effusions in the
speciﬁc context of Generalised Lymphatic Dysplasia however.9e11
To the best of our knowledge this is the ﬁrst such paediatric case
report. In our case there was symptomatic beneﬁt with some
objective improvement in lung function but ultimately reac-
cumulation of some pleural ﬂuid a year in to therapy. Admittedly,
there is also no way of knowing the relative contributions made by
the institution of prophylactic co-trimoxazole or a low-fat diet.
Roehr et al. published a systematic review identifying 35 chil-
dren in the medical literature treated with somatostatin or
octreotide for chylothorax.12 The cases identiﬁed were mainly post-
operative with none associated with Generalised LymphaticDysplasia. A positive treatment effect was reported in the majority.
Importantly, a number of side effects were noted. Aside fromminor
effects such as transient hyperglycaemia and cutaneous ﬂushing,
particular care is advised in childrenwho are vulnerable to vascular
insults and cases of strangulation-ileus in a child with asplenia and
necrotizing enterocolitis in a neonate with coarctation of the aorta
were cited.12
In conclusion, somatostatin analogues represent a potentially
useful treatment modality in children with chylothorax associated
with GLD and warrant consideration in cases refractory to other
management. Repeated thoracocentesis of chylothoraces may lead
to problems with nutrition and presents major practical issues in
children who may require general anaeasthesia for the procedure.4
Further studies are required to establish an evidence base for the
efﬁcacy and safety of somatostatin analogues; although the rarity of
this group of conditions makes it unlikely that a formal randomised
controlled trial will be feasible.12,13
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